Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

New ocular hypotensive agents in the Alcon pipeline

Sep. 8, 2000

New agents for glaucoma reported by Santen

Sep. 4, 2000

Visudyne sNDA granted priority review status

Sep. 1, 2000

Inspire reports synthesis of more stable P2Y2 agonists

Aug. 30, 2000

Allergan in-licenses gatifloxacin from Kyorin for treatment of ocular infections

Aug. 29, 2000

FDA approves Santen's levofloxacin eyedrops

Aug. 22, 2000

New compounds interacting with glutathione reductase useful for cataracts, etc.

Aug. 21, 2000

QLT and Ciba Vision seek expanded labeling for Visudyne

Aug. 18, 2000

Bausch & Lomb and Muro to copromote Optivar

Aug. 16, 2000

Retinoid supplementation improves mouse model of childhood blindness

Aug. 11, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 31, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026